Takeda Bets on China for Global Growth
- Japanese drugmaker will focus drug launch efforts on China
- CEO Weber is optimistic Shire deal will get China approval
This article is for subscribers only.
Takeda Pharmaceutical Co. sees China becoming a “core country” for its global growth strategy and is optimistic its $62 billion acquisition of Shire Plc will win approval by the country’s regulators.
Takeda is preparing to begin selling seven new drugs in China in the next five years, more than in any other region, while working to secure reimbursement for them under the country’s medical insurance program, Chief Executive Officer Christophe Weber said in an interview in Beijing. He didn’t say how many drugs would be introduced in other markets in that period.